Bavarian Nordic Secures $63M Order for Jynneos Mpox Vaccine

Bavarian Nordic has received a $63 million order from BARDA to produce Jynneos mpox vaccine doses. The contract will support the manufacturing of 1 million freeze-dried vaccines, set for delivery by 2026, according to the Danish biotech company.

Bavarian Nordic has announced the receipt of an additional $63 million order from the U.S. Biomedical Advanced Research and Development Authority (BARDA) for the production of its Jynneos mpox vaccine.

The contract stipulates the manufacturing of 1 million freeze-dried vaccine doses, which are expected to be delivered by the year 2026.

The Danish biotech company revealed this development on Tuesday, emphasizing its commitment to expanding vaccine accessibility and readiness.

(With inputs from agencies.)